共 40 条
- [31] Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600-mutant melanoma treated with first-line spartalizumab (S) plus dabrafenib (D) plus trametinib (T)JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)Dummer, ReinhardGusenleitner, DanielCampbell, Catarina D.Lebbe, CelesteAtkinson, VictoriaMandala, MarioNathan, Paul D.Arance, AnaRichtig, ErikaYamazaki, NaoyaRobert, CarolineSchadendorf, DirkTawbi, Hussein Abdul-HassanAscierto, Paolo AntonioRibas, AntoniFlaherty, KeithGasal, EduardBrase, Jan C.Long, Georgina V.
- [32] Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600-mutant melanoma treated with first-line spartalizumab (S) plus dabrafenib (D) plus trametinib (T).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Dummer, ReinhardGusenleitner, DanielCampbell, Catarina D.Lebbe, CelesteAtkinson, VictoriaMandala, MarioNathan, Paul D.Arance, AnaRichtig, ErikaYamazaki, NaoyaRobert, CarolineSchadendorf, DirkTawbi, Hussein Abdul-HassanAscierto, Paolo AntonioRibas, AntoniFlaherty, KeithGasal, EduardBrase, Jan C.Long, Georgina V.
- [33] BeyPro1: a Phase II single-arm study for the treatment after recurrence of advanced melanoma patients harboring the V600BRAF mutation and pretreated with Vemurafenib, with the association of Vemurafenib plus FotemustineEUROPEAN JOURNAL OF CANCER, 2015, 51 : S683 - S683Queirolo, P.Spagnolo, F.Picasso, V.Simeone, E.Grimaldi, A. M.Curvietto, M.Giorello, L.Fontana, V.Merlo, D. F.Ascierto, P. A.Bruzzi, P.
- [34] BeyPro1: A phase II single-arm study for the treatment after recurrence of advanced melanoma patients harboring the V600BRAF mutation and pretreated with vemurafenib, with the association of vemurafenib plus fotemustineJOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Queirolo, PaolaSpagnolo, FrancescoPicasso, VirginiaTornari, ElenaOttaviano, VincenzoGlorello, LauraSimeone, EsterGrimaldi, Antonio MariaCurvietto, MarcelloMario, Domenico FrancoAscierto, Paolo AntonioBruzzi, Paolo
- [35] A multi-center phase II study of high dose IL-2 (HD IL-2) sequenced with vemurafenib in patients with BRAF-V600E mutation positive advanced melanomaJOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Clark, JosephErnstoff, Marc S.Milhem, Mohammed M.Lao, Christopher D.Lawson, David H.Flaherty, Lawrence E.Luna, Theresa L.Aung, Sandra
- [36] BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets).JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Kirkwood, John M.Long, Georgina V.Trefzer, UweDavies, Michael A.Ascierto, Paolo AntonioChapman, Paul B.Puzanov, IgorHauschild, AxelRobert, CarolineKefford, RichardGoodman, Vicki L.Switzky, Julie C.Swann, R. SuzanneMartin, Anne-MarieGuckert, Mary E.Streit, Michael R. W.Schadendorf, Dirk
- [37] LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanomaEUROPEAN JOURNAL OF CANCER, 2015, 51 : S667 - S668Dummer, R.Sandhu, S.Hassel, J. C.Munoz, E.Berking, C.Gesierich, A.Ascierto, P. A.Esposito, O.Carter, K.Antona, V.Radhakrishnan, R.Cui, X.Caponigro, G.Jaeger, S.Demuth, T.Miller, W. H., Jr.
- [38] Preliminary findings from part 1 of COMBI-i: A phase III study of anti-PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)Dummer, ReinhardFernandez, Ana Maria AranceHansson, JohanLarkin, James M. G.Long, Georgina V.Gasal, EduardKaper, MathildeUpalawanna, AllisonMookerjee, BijoyeshVictoria
- [39] Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanomaJOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Long, Georgina V.Stroyakovskiy, DaniilGogas, HelenLevchenko, EvgenyDe Braud, Filippo G.Larkin, James M. G.Garbe, ClausJouary, ThomasHauschild, AxelGrob, Jean JacquesChiarion-Sileni, VannaLebbe, CelesteMandala, MarioMillward, MichaelDeMarini, Douglas JamesIrani, Jhangir G.Jin, FanSwann, R. SuzanneMookerjee, BijoyeshFlaherty, Keith
- [40] Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanomaEUROPEAN JOURNAL OF CANCER, 2015, 51 : S663 - S664Robert, C.Karaszewska, B.Schachter, J.Rutkowski, P.Mackiewicz, A.Stroyakovskiy, D.Lichinitser, M.Dummer, R.Grange, F.Mortier, L.Chiarion-Sileni, V.Drucis, K.Krajsova, I.Hauschild, A.Mookerjee, B.Legos, J.Schadendorf, D.